Drug Maker Concealed Collusive Activity From Investors, Shareholder Argues
Mealey's (November 9, 2016, 5:30 PM EST) -- NEW YORK — A pharmaceutical company and certain of its current and former executive officers misrepresented the company’s business and financial condition to investors and engaged in violations of federal antitrust...
To view the full article, register now.
Try for FREE for fourteen days
Already a subscriber? Click here to login